Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.61 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367363 | 0.90 | SCN9A (0.62) | SCN9ABCL2L1MCL1MAP4K4SCN5A | |
| SCHEMBL16242023 | 0.89 | SCN9A (0.57) | SCN9ABCL2L1MCL1SCN5A | |
| SCHEMBL364563 | 0.88 | SCN9A (0.59) | SCN9ABCL2L1MCL1MAP4K4SCN5A | |
| SCHEMBL16242117 | 0.86 | SCN9A (0.54) | SCN9ABCL2L1MCL1SCN5A | |
| SCHEMBL365660 | 0.85 | SCN9A (0.57) | SCN9ABCL2L1MCL1MAP4K4SCN5A | |
| SCHEMBL364550 | 0.84 | SCN9A (0.68) | SCN9ASCN5A | |
| SCHEMBL364579 | 0.83 | SCN9A (0.54) | SCN9ABCL2L1MCL1SCN5A | |
| SCHEMBL16242166 | 0.83 | SCN9A (0.55) | SCN9ABCL2L1MCL1SCN5A | |
| SCHEMBL367459 | 0.81 | SCN9A (0.64) | SCN9AMAP4K4SCN5A | |
| SCHEMBL10154795 | 0.81 | SCN9A (0.86) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593433-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-26 | — | — | EP | disclosed |
| EP-2593433-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116285-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2012007877-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116285-A1 | Chemical Compounds | SCN1A, SCN10A, SCN1B | SCN9A 9/4885BCL2L1 3291/4885MCL1 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.